HomeCompareFMEDX vs EQR

FMEDX vs EQR: Dividend Comparison 2026

FMEDX yields 17.73% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FMEDX wins by $15.7K in total portfolio value
10 years
FMEDX
FMEDX
● Live price
17.73%
Share price
$11.28
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.5K
Annual income
$5,247.63
Full FMEDX calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — FMEDX vs EQR

📍 FMEDX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFMEDXEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FMEDX + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FMEDX pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FMEDX
Annual income on $10K today (after 15% tax)
$1,507.09/yr
After 10yr DRIP, annual income (after tax)
$4,460.49/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EQR beats the other by $193.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FMEDX + EQR for your $10,000?

FMEDX: 50%EQR: 50%
100% EQR50/50100% FMEDX
Portfolio after 10yr
$55.6K
Annual income
$5,361.61/yr
Blended yield
9.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

FMEDX
No analyst data
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FMEDX buys
0
EQR buys
0
No recent congressional trades found for FMEDX or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFMEDXEQR
Forward yield17.73%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$63.5K$47.8K
Annual income after 10y$5,247.63$5,475.61
Total dividends collected$33.8K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: FMEDX vs EQR ($10,000, DRIP)

YearFMEDX PortfolioFMEDX Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$12,473$1,773.05$11,380$679.82+$1.1KFMEDX
2$15,413$2,066.85$13,014$837.25+$2.4KFMEDX
3$18,879$2,386.94$14,961$1,036.20+$3.9KFMEDX
4$22,933$2,732.41$17,297$1,289.22+$5.6KFMEDX
5$27,640$3,102.01$20,121$1,613.15+$7.5KFMEDX
6$33,069$3,494.15$23,561$2,030.84+$9.5KFMEDX
7$39,291$3,906.97$27,783$2,573.54+$11.5KFMEDX
8$46,380$4,338.36$33,013$3,284.39+$13.4KFMEDX
9$54,412$4,786.05$39,547$4,223.51+$14.9KFMEDX
10$63,469$5,247.63$47,791$5,475.61+$15.7KFMEDX

FMEDX vs EQR: Complete Analysis 2026

FMEDXStock

Normally the fund invests at least 80% of assets in securities of disruptive medicine companies. Normally it invests primarily in equity securities. Companies within the disruptive medicine theme include but are not limited to those companies that, in the Adviser's opinion, are engaged in robotic surgery, gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based health care platforms, and consumer wellness. The fund is non-diversified.

Full FMEDX Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this FMEDX vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FMEDX vs SCHDFMEDX vs JEPIFMEDX vs OFMEDX vs KOFMEDX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.